Candida Parapsilosis + Krusei IgA

This test looks for IgA antibodies in serum aimed at two yeasts called Candida parapsilosis and Candida krusei. Serum is the clear part of blood left after clotting. Antibodies are a running record your immune system keeps of what it has met and reacted to. A higher level can suggest your body has made a stronger response to these fungi somewhere along its inner surfaces.

Read your number with two caveats in mind. This is a research-grade marker with no agreed-upon cutoff, and most of the published science behind it studied related tests rather than this exact one. Treat the result as a signal to weigh against how you feel and what else is going on, not an answer on its own.

What this test actually measures

The molecule being counted is IgA. IgA is the antibody class that patrols your moist inner linings: the gut, mouth, urinary tract, and genital tract. Most IgA works at those surfaces. A smaller amount circulates in blood, and that circulating fraction is what this serum test measures.

The lab coats a plate with Candida proteins and sugars, adds your serum, and measures how much of your IgA sticks. More binding usually means more immune recognition of Candida material. The test is a readout of how much fungal material your immune system has been seeing, not whether a culture would grow the organism.

Why the level goes up

Candida species can live harmlessly on skin and the lining of the mouth, gut, urinary tract, and genital tract. When they shift from quiet residents to active colonizers or invaders, the cells lining those surfaces raise an alarm, immune cells arrive, and antibody-making cells start producing antibodies against fungal cell-wall sugars and proteins. IgA is one of the classes they produce.

In repeat blood draws during active Candida infection, anti-Candida antibodies climbed over days. IgM often rose before IgG and IgA, though the order is not uniform and IgG responses can outpace IgM. That sequence is why a single snapshot can miss a response that is still building. This timing came from studies of general anti-Candida antibodies, not this species-pairing IgA test.

Oral thrush in HIV

The clearest human signal comes from people with HIV. Those with active oral thrush had higher serum IgA against Candida albicans than HIV-positive people without thrush and healthy controls, including antibodies to the yeast's tissue-digesting enzymes, though the study was small. This fits the idea that a visible infection on a moist surface can drive a measurable rise in circulating anti-Candida IgA. The catch: those studies measured Candida albicans, a related species, not C. parapsilosis or C. krusei.

Gut inflammation, yeast or not

A high anti-Candida IgA does not always mean yeast is the problem. Crohn's disease and orofacial granulomatosis inflame the gut and mouth. In people with those conditions, serum IgA to Candida albicans was high across patient groups. The likely reason is that an inflamed lining lets more fungal material through, so the antibody rises as a marker of barrier irritation rather than active yeast infection.

That is the point to keep in mind: this is not a simple good-number, bad-number marker. A rise can mean an active yeast infection, general inflammation at a moist surface, or heavy colonization by a normal resident. A low reading is not automatically reassuring either. In HIV patients, low Candida-reactive IgA in saliva went with a heavier oral fungal load, hinting at weaker local defense. That was saliva, not serum, so it should not be read as a rule for this blood test.

The two yeasts are not the same threat

It helps to know what these species do when they turn serious, which happens mostly in hospitals, not in everyday outpatient life. Candida krusei is naturally resistant to fluconazole, a common antifungal. In bloodstream infection, it is one of the Candida species with the highest short-term mortality. In the PATH registry, just over half of patients with C. krusei bloodstream infection died within 12 weeks, and many had blood cancers, stem cell transplants, neutropenia, or steroid exposure.

Candida parapsilosis usually behaves differently in bloodstream infection. In the same registry, about a quarter of patients died within 12 weeks. It is strongly tied to catheters, IV nutrition, and layers of yeast stuck to medical devices rather than deep immune failure alone. Neither bloodstream picture is what a serum antibody in a well outpatient reflects. The species names on your result signal which yeasts your immune system reacted to, not that you have a dangerous invasive infection.

Why one reading tells you little

A single positive is weak evidence on its own. In routine mycology labs, first Candida antibody samples were positive in about 2 in 100 for IgA and about 6 in 100 for IgG or IgM. A one-off result sits in a noisy background. And because IgA can rise later than IgM, one draw can catch a response mid-climb or after it has faded.

A 2026 ICU study made the same warning from another angle. Candida antigen tests rose with invasive infection, while anti-Candida antibodies were more tied to colonization. Those were C. albicans-based antibody assays in ICU patients, not this exact outpatient species pair. But the warning travels: antibody is context, not diagnosis.

This is why repeats can carry more weight than a single value. A steady rise across IgA, IgG, and IgM carries more weight than one IgA result. The strongest evidence for this sequential reading came from general anti-Candida antibody studies, so apply it as a principle rather than a validated protocol for this exact test.

What to do with an out-of-pattern result

A positive IgA is a reason to look further, not a reason to start antifungals. On its own it cannot separate colonization from infection. It also should not be treated as species proof, because Candida antibody and antigen assays can react with shared Candida cell-wall sugars, and this exact C. parapsilosis/C. krusei IgA pairing is not well validated in outcome studies.

Match the next step to how you feel. If you have real symptoms, recurrent vaginal or urinary yeast, or a device like a catheter, check a culture or PCR from the affected site. Beta-D-glucan looks for fungal cell-wall material in blood. Candida PCR looks for fungal DNA. These are not the same as culture, but they test for organism or fungal material rather than your immune memory. If you are frankly ill, feverish, immune-suppressed, or have a central line, that is a clinical situation for a doctor and often an infectious disease specialist, not something to manage from a home result.

If you feel well and the elevation is modest, the useful context is your gut. Recent antibiotics, digestive symptoms, or a known inflammatory bowel condition can all lift this marker without an active yeast infection. In that case, the trend plus attention to whatever else is inflaming your gut tells you more than acting on the single number.

When results can be misleading

• Shared Candida targets: Candida antibodies and antigen tests can react with shared cell-wall sugars, so a result should not be used by itself to prove which species is present today.
• Colonization versus infection: Candida is a normal resident of skin and moist linings, so antibodies can be present in healthy people with no invasive disease.
• Background gut inflammation: conditions like Crohn's disease can raise serum anti-Candida IgA through an inflamed lining, not through active yeast infection.
• Low total IgA: if your body makes little IgA overall, a low anti-Candida IgA may understate reactivity to the yeast.
• Antifungal treatment: antifungals can reduce organism burden and can lower some fungal antigen markers. Short-term effects on this serum IgA test are not well established, so don't use a treated result as clean evidence either way.